StockData
Myriad Genetics Inc logo

Myriad Genetics Inc (MYGN) stock

MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/3070% below fair value
$5.54−0.03 (-0.54%)

Close on Nov 17, 2026Market cap $529.90MP/E –Yield –

Myriad Genetics cash

Cash and short-term investments held at the end of each period.

Myriad Genetics's cash was $115.20M at Jun 30, 2026. For fiscal 2025 it was $149.60M, up 33.7% from the year before. Over ten years it grew -2.2% a year on average. The highest annual figure on record is $488.38M in fiscal 2010.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$149.60M+33.7%
FY2024Dec 31, 2024$111.90M-20.6%
FY2023Dec 31, 2023$140.90M-17.0%
FY2022Dec 31, 2022$169.70M-33.4%
FY2020Jun 30, 2020$254.80M+32.8%
FY2019Jun 30, 2019$191.80M+6.2%
FY2018Jun 30, 2018$180.60M+19.8%
FY2017Jun 30, 2017$150.70M-5.2%
FY2016Jun 30, 2016$159.00M+9.8%
FY2015Jun 30, 2015$144.80M-22.3%
FY2014Jun 30, 2014$186.40M-49.9%
FY2013Jun 30, 2013$372.34M+9.3%
FY2012Jun 30, 2012$340.58M-18.4%
FY2011Jun 30, 2011$417.31M-14.6%
FY2010Jun 30, 2010$488.38M+669.0%
FY2009Jun 30, 2009$63.51M-73.3%
FY2008Jun 30, 2008$237.73M–

Quarterly cash

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026$115.20M+54.8%
Q1 FY2026CQ1 2026Mar 31, 2026$124.40M+35.5%
Q4 FY2025CQ4 2025Dec 31, 2025$149.60M+33.7%
Q3 FY2025CQ3 2025Sep 30, 2025$145.40M+45.5%
Q2 FY2025CQ2 2025Jun 30, 2025$74.40M-23.5%
Q1 FY2025CQ1 2025Mar 31, 2025$91.80M-12.0%
Q4 FY2024CQ4 2024Dec 31, 2024$111.90M-20.6%
Q3 FY2024CQ3 2024Sep 30, 2024$99.90M+15.8%
Q2 FY2024CQ2 2024Jun 30, 2024$97.30M-20.0%
Q1 FY2024CQ1 2024Mar 31, 2024$104.30M+32.5%
Q4 FY2023CQ4 2023Dec 31, 2023$140.90M-17.0%
Q3 FY2023CQ3 2023Sep 30, 2023$86.30M-54.9%
Q2 FY2023CQ2 2023Jun 30, 2023$121.60M-40.4%
Q1 FY2023CQ1 2023Mar 31, 2023$78.70M-70.6%
Q4 FY2022CQ4 2022Dec 31, 2022$169.70M-33.4%
Q3 FY2022CQ3 2022Sep 30, 2022$191.20M+5.3%
Q2 FY2022CQ2 2022Jun 30, 2022$204.10M+44.1%
Q1 FY2022CQ1 2022Mar 31, 2022$267.40M+87.5%
Q4 FY2020CQ2 2020Jun 30, 2020$254.80M+32.8%
Q3 FY2020CQ1 2020Mar 31, 2020$181.50M+21.2%
Q2 FY2020CQ4 2019Dec 31, 2019$141.60M-14.4%
Q1 FY2020CQ3 2019Sep 30, 2019$142.60M-14.9%
Q4 FY2019CQ2 2019Jun 30, 2019$191.80M+6.2%
Q3 FY2019CQ1 2019Mar 31, 2019$149.70M-4.8%
Q2 FY2019CQ4 2018Dec 31, 2018$165.40M+15.3%
Q1 FY2019CQ3 2018Sep 30, 2018$167.50M+12.9%
Q4 FY2018CQ2 2018Jun 30, 2018$180.60M+19.8%
Q3 FY2018CQ1 2018Mar 31, 2018$157.30M-8.6%
Q2 FY2018CQ4 2017Dec 31, 2017$143.50M-11.6%
Q1 FY2018CQ3 2017Sep 30, 2017$148.30M-0.1%
Q4 FY2017CQ2 2017Jun 30, 2017$150.70M-5.2%
Q3 FY2017CQ1 2017Mar 31, 2017$172.10M-20.6%
Q2 FY2017CQ4 2016Dec 31, 2016$162.40M-25.9%
Q1 FY2017CQ3 2016Sep 30, 2016$148.40M-4.5%
Q4 FY2016CQ2 2016Jun 30, 2016$159.00M+9.8%
Q3 FY2016CQ1 2016Mar 31, 2016$216.70M+61.2%
Q2 FY2016CQ4 2015Dec 31, 2015$219.30M–
Q1 FY2016CQ3 2015Sep 30, 2015$155.40M–
Q4 FY2015CQ2 2015Jun 30, 2015$144.80M–
Q3 FY2015CQ1 2015Mar 31, 2015$134.42M–

More Myriad Genetics figures

See a number that looks wrong?